The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of cetuximab (cet) in combination with S-1 and irinotecan (iri) (SIRC) in first-line treatment for metastatic colorectal cancer (mCRC) (JACCRO CC-10).
 
Akihito Tsuji
Honoraria - Merck Serono; Taiho Pharmaceutical
 
Masato Nakamura
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Toshiki Masuishi
No Relationships to Disclose
 
Masahito Kotaka
No Relationships to Disclose
 
Ken Shimada
No Relationships to Disclose
 
Mitsugu Kochi
No Relationships to Disclose
 
Masahiro Takeuchi
Honoraria - Takeda
Consulting or Advisory Role - AstraZeneca; Hisamitsu Pharmaceutical; Shionogi; Taiho Pharmaceutical
 
Wataru Ichikawa
Honoraria - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Consulting or Advisory Role - Merck Serono
 
Masashi Fujii
Stock and Other Ownership Interests - Otsuka (I)
Consulting or Advisory Role - Taiho Pharmaceutical
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization
 
Toshifusa Nakajima
No Relationships to Disclose